Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JMJD6 | Q6NYC1 | 8/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.51 |
| ▸ | WNT1 | P04628 | 1/20 | 0.47 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.43 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.43 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19706503 | 0.89 | PIK3C3 (0.51) | JMJD6DYRK1AWNT1PIK3C3 | |
| SCHEMBL19699521 | 0.85 | DYRK1A (0.48) | JMJD6DYRK1AWNT1PIK3C3IKBKE | |
| SCHEMBL15885857 | 0.82 | IRAK4 (0.55) | JMJD6DYRK1AWNT1PIK3C3GSK3B | |
| SCHEMBL17240207 | 0.76 | L3MBTL1 (0.49) | PIK3C3GSK3BNR3C2EGFR | |
| SCHEMBL31706103 | 0.75 | JMJD6 (0.62) | JMJD6IKBKETBK1KMT2A | |
| SCHEMBL31706726 | 0.75 | JMJD6 (0.62) | JMJD6IKBKETBK1KMT2A | |
| SCHEMBL29796107 | 0.75 | KMT2A (0.53) | KMT2A | |
| SCHEMBL30510109 | 0.75 | JMJD6 (0.51) | JMJD6DYRK1AKMT2APIP5K1C | |
| SCHEMBL15885529 | 0.75 | JMJD6 (0.51) | JMJD6DYRK1AKMT2APIP5K1C | |
| SCHEMBL17872874 | 0.75 | KDM4E (0.51) | DYRK1AGSK3BEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2944637-B1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM CORP (JP) | 2020-02-19 | — | — | EP | disclosed |
| US-9783536-B2 | Nitrogen-containing heterocyclic compound or salt thereof | FUJIFILM CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| EP-2944637-A1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM Corporation (JP) | 2015-11-18 | — | — | EP | disclosed |
| US-20150322063-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322063-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | NPM1, NAP1L1, REN | JMJD6 1669/4885DYRK1A 4462/4885WNT1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.